NBIX Earnings

NBIX reported its earnings on 2026-02-11, showcasing a revenue of 805.50M against an estimate of 782.91M, resulting in a 2.89% surprise. The EPS was 1.88, surpassing the expected 1.8 by 4.44%. The stock experienced a -10.43% price change on the earnings day and a -6.59% change over the next five days, reflecting market reactions to the results.

Following NBIX's earnings announcement on 2026-02-11, the stock price moved by -10.43% on the day of the release. Over the subsequent five days, it saw a -6.59% change. Historically, NBIX's stock price tends to shift by an average of -3.33% in the 10 days leading up to earnings and -2.08% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate NBIX's annual revenue to reach 773.97M, while the EPS is projected at 1.99. These estimates reflect recent revisions, with revenue estimates revised downward by -0.03% and EPS estimates revised downward by -0.1% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NBIX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.03%, while EPS estimates moved revised downward by -0.1%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NBIX's stock price typically moves by -3.33% in the 10 days before its earnings and -2.08% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.99 and revenue of 773.97M.

The earnings call summary and Q&A highlight several positive aspects: strong clinical progress, sales force expansion, and favorable feedback on CRENESSITY. Despite increased SG&A expenses, the anticipated growth in INGREZZA and CRENESSITY, along with positive KOL feedback, indicates a positive outlook. However, the lack of specific guidance and some management ambiguity slightly temper the sentiment, preventing a 'Strong positive' rating. Overall, the strategic investments and market expansion plans suggest a likely positive stock price movement over the next two weeks.